Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter controlled trial of NP029 in dialysis shunt insufficiency
jRCT2032220478Active, not recruiting
- Sponsor
- Nipro Corporation
- Start
- Jul 2022
- Countries
- 1
01
Overview
Randomised trial in dialysis access dysfunction (VAF) (2 arms), sponsored by Nipro Corporation. Primary endpoint: Primary patency rate of target lesions up to 6 months. Started Jul 2022; status: active, not recruiting.
02
Conditions
dialysis access dysfunction (VAF)
Beyond the preview
Go deeper on jRCT2032220478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2032220478.